Business Standard

Novavax says its Covid-19 vaccine gets India authorisation for teens

The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.

FILE - This Wednesday, Oct. 7, 2020 file photo shows a vial of the Phase 3 Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. (Photo: AP)
Premium

FILE PHOTO: Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. (Photo: AP)

Reuters
Novavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.

The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.

Novavax last month said its vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.

The company said on Tuesday its vaccine produced an immune response in the same age group in a mid- to

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 24 2022 | 12:45 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com